7. Aranson S.The pancreas. R I Med J.1994;77:97-99.
8.
8. Minkowski O.Historical development of the theory of pancreatic diabetes. Dia-betes. 1929, reprinted 1989;38:1-6.
9.
9. Labhart A.Intuition, luck and misfortune. Diabeto-logia.1978;(14):353-358.
10.
10. Banting F, Best C, Collip J, Campbell W, Fletcher A.Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. Can Med Assoc J.1922, reprinted 1991;145:1281-1286.
11.
11. Dinsmoor R.Insulin: a never ending evolution. Countdown. 2001;Spring: 46-52.
12.
12. Johansson B-L, Fernqvizdt-Forbes E, Wahren J.Effects of C-peptide on nephropathy and neuropathy in IDDM patients a clinical study. Diabetologia. 1995; 38(suppl 1):A7-A7.
13.
13. Tattersal R.The quest for normoglycaemia: a historical perspective. Diabetic Med.1994;11:618-635.
14.
14. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993;329:977-986.
15.
15. Joslin E.Status of living diabetics with onset under forty years of age. JAMA. 1951;147:209-213.
16.
16. Tolstoi E.Newer concepts in the treatment of diabetes mellitus with protamine insulin. Am J Digest Dis.1943;10:247-247.
17.
17. Dunlop D.Are diabetic degeneration complications preventable?Br Med J.1954;Aug:383-385.
18.
18. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lan-cet.1998;352:837-853.